share_log
Reuters ·  2024/11/16 00:01

Arbutus and Barinthus Bio Announce New Data From the IM-Prove II Trial Showing That the Addition of Nivolumab Increased Rates of Hbsag Loss in People With Chronic Hepatitis B

Arbutus和Barinthus Bio宣布了Im-Prove II试验的新数据,显示尼伏单抗的添加提高了慢性乙型肝炎患者Hbsag丢失的比率。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发